Cited by 701Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Glial reactions in Parkinson's disease

McGeer, Patrick L., McGeer, Edith G.·2008·Movement Disorders

DOI 10.1002/mds.21751

Open this paper in CoChat — free account

Abstract

Dopaminergic neurons of the substantia nigra are particularly vulnerable to oxidative and inflammatory attack. Such processes may play a crucial role in the etiology of Parkinson disease (PD). Since glia are the main generators of these processes, the possibility that PD may be caused by glial dysfunction needs to be considered. This review concentrates on glial reactions in PD. Reactive astrocytes and reactive microglia are abundant in the substantia nigra (SN) of PD cases indicating a robust inflammatory state. Glia normally serve neuroprotective roles but, given adverse stimulation, they may contribute to damaging chronic inflammation. Microglia, the phagocytes of brain, may be the main contributors since they can produce large numbers of superoxide anions and other neurotoxins. Their toxicity towards dopaminergic neurons has been demonstrated in tissue culture and various animal models of PD. The MPTP and α‐synuclein models are of particular interest. Years after exposure to MPTP, inflammation has been observed in the SN. This has established that an acute insult to the SN can result in a sustained local inflammation. The α‐synuclein model indicates that an endogenous protein can induce inflammation, and, when overexpressed, can lead to autosomal dominant PD. Less is known about the role of astrocytes than microglia, but they are known to secrete both inflammatory and anti‐inflammatory molecules and may play a role in modulating microglial activity. Oligodendrocytes do not seem to play a role in promoting inflammation although, like neurons, they may be damaged by inflammatory processes. Further research concerning glial reactions in PD may lead to disease‐modifying therapeutic approaches. © 2007 Movement Disorder Society

Integrity signals

Registry

Crossref · 10.1002/mds.21751

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Self-citation
α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
The many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A. M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,063
Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia
Kim, W., Mohney, R. P., Wilson, B. C., Jeohn, G., Liu, B., & Hong, J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 881
Microglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 869
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease
Kim, Y. S., & Joh, T. H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.40 · Cited by 655
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 641
Inflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 632
Self-citation
ASTROCYTIC NEUROTRANSMITTER RECEPTORS IN SITU AND IN VIVO
Porter, J. T., & McCarthy, K. D. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00068-8 · Cited by 514
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Self-citation
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 481
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease
Bandopadhyay, R. (2004) · Brain · doi:10.1093/brain/awh054 · Cited by 475
NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains
Wakabayashi, K., Hayashi, S., Yoshimoto, M., Kudo, H., & Takahashi, H. (2000) · Acta Neuropathologica · doi:10.1007/pl00007400 · Cited by 451
Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons
Gao, H., Hong, J., Zhang, W., & Liu, B. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00782.2002 · Cited by 439
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Inflammatory Process in Parkinsons Disease: Role for Cytokines
Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging
Cicchetti, F., Brownell, A., Williams, K. S., Chen, Y. I., Livni, E., & Ole Isacson, A. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Self-citation
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371
Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 370
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 362
Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes
Chen, P.-S., Peng, G.-S., Li, G., Yang, S., Wu, X., Wang, C. C., Wilson, B. C., Lu, R.-B., Gean, P.-W., Chuang, D.-M., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001893 · Cited by 356
MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons
Petrova, P. S., Raibekas, A. A., Pevsner, J., Vigo, N. T., Anafi, M., Moore, M. K., Peaire, A. E., Shridhar, V., Smith, D. I., Kelly, J., et al. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:2:173 · Cited by 353
Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons
Gao, H., Liu, B., & Hong, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06181.2003 · Cited by 338
Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease
Wilms, H., Rosenstiel, P. C., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R. S., Anisman, H., Hayley, S. P., & Park, D. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 331
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331
The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease
Mirza, B., Hadberg, H., Thomsen, P., & Moos, T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00455-8 · Cited by 327
Selective microglial activation in the rat rotenone model of Parkinson's disease
Sherer, T., Betarbet, R. S., Kim, J.-H., & Greenamyre, J. T. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00172-1 · Cited by 317
Neuroinflammatory processes in Parkinson's disease
Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 303
The expression and function of chemokines involved in CNS inflammation
Ubogu, E. E., Cossoy, M. B., & Ransohoff, R. M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.002 · Cited by 281
Microglial Activation and Dopaminergic Cell Injury: AnIn VitroModel Relevant to Parkinson's Disease
Le, W. D., Rowe, D. B., Xie, W., Ortiz, I., He, Y., & Appel, S. H. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08447.2001 · Cited by 274
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys
Judith Miklossy, A., Doudet, D., Schwab, C., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255
Self-citation
Nrf2-mediated protection against 6-hydroxydopamine
Jakel, R. J., Townsend, J. A., Kraft, A. D., & Johnson, J. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.131 · Cited by 252
Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease
Gao, H., Hong, J., Zhang, W., & Liu, B. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01228.2003 · Cited by 251
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration.
Iravani, M. M., Kashefi, K., Mander, P., Rose, S., & Jenner, P. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00562-0 · Cited by 247
Dopamine and noradrenaline control distinct functions in rodent microglial cells
Färber, K., Pannasch, U., & Kettenmann, H. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.01.003 · Cited by 247
Non-steroidal anti-inflammatory drugs in Parkinson's disease
Esposito, E., Matteo, V. D., Benigno, A., Pierucci, M., Crescimanno, G., & Giovanni, G. D. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.008 · Cited by 237
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease
Depino, A. M., Earl, C. D., Kaczmarczyk, E., Ferrari, C. C., Besedovsky, H. O., del Rey, A., Pitossi, F. J., & Oertel, W. H. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03014.x · Cited by 237
Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins
Yamada, T., McGeer, P. L., & McGeer, E. G. (1992) · Acta Neuropathologica · doi:10.1007/bf00427222 · Cited by 231
Self-citation
Chapter 36: Astrocytes and Parkinson's disease
Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. A. D., & Langston, J. W. (1992) · Progress in brain research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227
Self-citation
The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease
Campbell, B. C. V., McLean, C., Culvenor, J. G., Gai, W., Blumbergs, P. C., Jäkälä, P., Beyreuther, K. T., Masters, C. L., & Li, Q. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00021.x · Cited by 226
Effects of norepinephrine on rat cultured microglial cells that express α1, α2, β1 and β2 adrenergic receptors
Mori, K., Ozaki, E., Zhang, B., Yang, L., Yokoyama, A., Takeda, I., Maeda, N., Sakanaka, M., & Tanaka, J. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00211-3 · Cited by 215
Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure
Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206
Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration.
Arimoto, T., & Bing, G. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(02)00017-7 · Cited by 202
A pivotal role of matrix metalloproteinase‐3 activity in dopaminergic neuronal degeneration via microglial activation
Kim, Y. S., Choi, D. H., Block, M. L., Lorenzl, S., Yang, L., Kim, Y., Sugama, S., Cho, B. P., Hwang, O., Browne, S. E., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5865com · Cited by 199
LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines
Judith Miklossy, A., Arai, T., Guo, J., Klegeris, A., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000235121.98052.54 · Cited by 183
Self-citation
To be or not to be (inflamed)—is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
Marchetti, B., & Abbracchio, M. P. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.08.007 · Cited by 175
Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein
Zhang, W., Dallas, S., Zhang, D., Guo, J., Pang, H., Wilson, B. C., Miller, D. S., Chen, B., Zhang, W., McGeer, P. L., et al. (2007) · Glia · doi:10.1002/glia.20532 · Cited by 166
Self-citation
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline
Casarejos, M. J., Menéndez, J., Solano, R. M., Rodríguez‐Navarro, J. A., de Yébenes, J. G., & Mena, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03777.x · Cited by 156
Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice
Sugama, S., Yang, L., Cho, B. P., DeGiorgio, L. A., Lorenzl, S., Albers, D. S., Beal, M. F., Volpe, B. T., & Joh, T. H. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04085-4 · Cited by 153
α-Synuclein Expression Modulates Microglial Activation Phenotype
Austin, S. A., Floden, A. M., Murphy, E. J., & Combs, C. K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-06.2006 · Cited by 150
Free radicals in Parkinson's disease
Koutsilieri, E., Scheller, C., Grünblatt, E., Keinosuke, N. A. R. A., Li, J., & Riederer, P. F. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1201-7 · Cited by 117
Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors
Keyser, J. D., Wilczak, N., Leta, R., & Streetland, C. (1999) · Neurology · doi:10.1212/wnl.53.8.1628 · Cited by 114
Upregulation of Protease-Activated Receptor-1 in Astrocytes in Parkinson Disease: Astrocyte-Mediated Neuroprotection Through Increased Levels of Glutathione Peroxidase
Ishida, Y., Nagai, A., Kobayashi, S., & Kim, S. U. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000195941.48033.eb · Cited by 109
Existence of functional β1‐ and β2‐adrenergic receptors on microglia
Tanaka, K. F., Kashima, H., Suzuki, H., Ono, K., & Sawada, M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10399 · Cited by 105
Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease
Shaik, S., Combs, C. K., & Ebadi, M. (2006) · Neurochemical Research · doi:10.1007/s11064-005-9233-x · Cited by 104
Dopamine-derived Dopaminochrome Promotes H2O2 Release at Mitochondrial Complex I
Zoccarato, F., Toscano, P., & Alexandre, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500657200 · Cited by 100
The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity
Noelker, C., Bacher, M., Gocke, P., Wei, X., Klockgether, T., Du, Y., & Dodel, R. C. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.04.023 · Cited by 100
Chromogranin A Induces a Neurotoxic Phenotype in Brain Microglial Cells
Ciesielski-Treska, J., Ulrich, G., Taupenot, L., Chasserot‐Golaz, S., Corti, A., Aunis, D., & Bader, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14339 · Cited by 100
Role of Fcγ Receptors in Nigral Cell Injury Induced by Parkinson Disease Immunoglobulin Injection into Mouse Substantia Nigra
He, Y., Le, W., & Appel, S. H. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7946 · Cited by 97
Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage
Li, G., Cui, G., Tzeng, N., Wei, S., Wang, T., Block, M. L., & Hong, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2555com · Cited by 96
Thrombin‐activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: Dual roles of mitogen‐activated protein kinase signaling pathways
Lee, D. Y., Oh, Y. J., & Jin, B. K. (2005) · Glia · doi:10.1002/glia.20190 · Cited by 88
3‐Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP‐elicited damage both in vivo and in vitro
Zhang, W., Shin, E., Wang, T., Lee, P. H., Pang, H., Wie, M., Kim, W., Kim, S., Huang, W., Wang, Y., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6006com · Cited by 76
Parkinson's disease and inflammatory changes
Barcia, C., Barreiro, A. F., Poza, M., & Herrero, M. T. (2003) · Neurotoxicity Research · doi:10.1007/bf03033170 · Cited by 76
Chemokines in the MPTP model of Parkinson’s disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration
Kalkonde, Y. V., MORGAN, W. W., Sigala, J. A., Maffi, S. K., Condello, C., Kuziel, W. A., Ahuja, S. S., & Ahuja, S. K. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.041 · Cited by 75
CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system.
Chen, K., Huang, J., Gong, W., Zhang, L., Yu, P., & Wang, J. M. (2006) · PubMed · Cited by 75
Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells
Klegeris, A., & McGeer, P. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 73
Self-citation
3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicity
Zhang, W., Qin, L., Wang, T., Wei, S., Gao, H., Liu, J., Wilson, B. C., Liu, B., Zhang, W., Kim, H., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-1586fje · Cited by 70
Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra
Knott, C., Stern, G. M., Kingsbury, A. E., Welcher, A. A., & Wilkin, G. P. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00008-1 · Cited by 68
Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants
Klegeris, A., & McGeer, P. L. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90067-1 · Cited by 68
Self-citation
Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: Role of microglia
Ryu, J. K., Shin, W. H., Kim, J., Joe, E. H., Lee, Y. B., Cho, K. G., Oh, Y. J., Kim, S. U., & Jin, B. K. (2002) · Glia · doi:10.1002/glia.10047 · Cited by 61
Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: Role of neuron–glia crosstalk
Saavedra, A., Baltazar, G., Rodrigues‐Santos, P., Carvalho, C. M., & Duarte, E. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.008 · Cited by 61
A Synthetic Derivative of the Natural Product Rocaglaol Is a Potent Inhibitor of Cytokine-Mediated Signaling and Shows Neuroprotective Activity in Vitro and in Animal Models of Parkinson’s Disease and Traumatic Brain Injury
Fahrig, T., Gerlach, I., & Horváth, E. J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008177 · Cited by 59
Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases
Yasuhara, O., Kawamata, T., Aimi, Y., McGeer, E. G., & McGeer, P. L. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90227-5 · Cited by 58
Self-citation
Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity
McLaughlin, P., Zhou, Y., Ma, T., Liu, J., Zhang, W., Hong, J., Kovacs, M., & Zhang, J. (2006) · Glia · doi:10.1002/glia.20294 · Cited by 55
Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase‐2 via CD40: Relevance to Parkinson's disease
Okuno, T., Nakatsuji, Y., Kumanogoh, A., Moriya, M., Ichinose, H., Sumi, H., Fujimura, H., Kikutani, H., & Sakoda, S. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20599 · Cited by 54
Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: Role of microglia
Wang, X., Yan, Z.-Q., Lü, G., Stuart, S., & Chen, S. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.07.014 · Cited by 52
Amyloid β and neuromelanin—Toxic or protective molecules?The cellular context makes the difference
Rao, K. S. J., Hegde, M. L., Anitha, S., Musicco, M., Zucca, F. A., TURRO, N. J., & Zecca, L. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.03.004 · Cited by 49
Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Hayley, S. P., & Anisman, H. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381611 · Cited by 38
Reactive microgliosis participates in MPP + ‐induced dopaminergic neurodegeneration: role of 67 kDa laminin receptor
Wang, T., Zhang, W., Pei, Z., Block, M. L., Wilson, B. C., Reece, J. M., Miller, D. S., & Hong, J. (2006) · The FASEB Journal · doi:10.1096/fj.05-5053com · Cited by 36
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(−)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease
Kato, H. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00411-2 · Cited by 33
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: Implications in Parkinson's disease
Jana, S., Maiti, A. K., Bagh, M. B., Banerjee, K., Das, A., Roy, A., & Chakrabarti, S. (2007) · Brain Research · doi:10.1016/j.brainres.2006.09.100 · Cited by 33
Some Immunohistochemical Features of Argyrophilic Grain Dementia With Normal Cortical Choline Acetyltransferase Levels but Extensive Subcortical Pathology and Markedly Reduced Dopamine
Yamada, T., McGeer, P. L., & McGeer, E. G. (1992) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/002383099200500102 · Cited by 31
Self-citation
Relationship of Complement-Activated Oligodendrocytes to Reactive Microglia and Neuronal Pathology in Neurodegenerative Disease
Yamada, T., McGeer, P. L., & McGeer, E. G. (1991) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107179 · Cited by 28
Self-citation
Anti-inflammatory activity of pergolide, a dopamine receptor agonist.
Bendele, A. M., Spaethe, S. M., Benslay, D. N., & Bryant, H. U. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20353-6 · Cited by 27
GT1b ganglioside induces death of dopaminergic neurons in rat mesencephalic cultures
Chung, E. S., Joe, E. H., Ryu, J. K., Kim, J., Lee, Y. B., Cho, K. G., Oh, Y. J., Maeng, S. H., Baik, H. H., Kim, S. U., et al. (2001) · Neuroreport · doi:10.1097/00001756-200103050-00036 · Cited by 24
Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons
Aimi, Y., & McGeer, P. L. (1996) · Parkinsonism & Related Disorders · doi:10.1016/1353-8020(96)00004-1 · Cited by 16
Self-citation
The involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer’s disease
Walker, D. G., Lue, L., Klegeris, A., & McGeer, P. L. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_9 · Cited by 4
Self-citation
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1

Research works printed but not linked: 5

Del Rio Hortega P, 1919, El ‘tercer elemento’ de los centros nerviosos. Poder fagocitario y movilidad de la microglia, Bol Soc Esp Biol Ano, 154
LeWD RoweDB XieW.Activated microglia induce dopaminergic cell injury in vitro. In: Proceedings of the XIII International Congress on Parkinson's Disease Vancouver Canada July1999. pS19.
10.1111/j.1460-9568.2003.03014.x · DOI
10.1006/exnr.2002.7946 · DOI
10.1096/fj.05-5053com · DOI

Sorted by citations

Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70238-8 · Cited by 972

See all 701

Authors: McGeer, P. L., & McGeer, E. G.
Affiliations: University of British Columbia (CA)
Corresponding author: McGeer, Patrick L.
ORCID: McGeer, Patrick L.
Venue: Movement Disorders
Publisher: Wiley
Published: 2007-11-28
Volume: 23
Issue: 4
Pages: 474-483
ISSN: 0885-3185 (ISSN-L)
1531-8257
DOI: 10.1002/mds.21751
OpenAlex: W2120412340
Cited by: 701
References: 106
Citations by year: 2026: 9 · 2025: 23 · 2024: 20 · 2023: 20 · 2022: 36 · 2021: 26 · 2020: 39 · 2019: 22 · 2018: 42 · 2017: 34 · 2016: 48 · 2015: 39 · 2014: 58 · 2013: 40 · 2012: 63
FWCI: 5.11
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Movement Disorders (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, glial reaction, reactive astrocytes, reactive microglia, substantia nigra, dopaminergic neurons, neuroinflammation, oxidative stress, MPTP, alpha-synuclein, oligodendrocytes, neuroprotection, disease-modifying therapy
MeSH terms: Animals, Haplorhini, Anti-Inflammatory Agents, Non-Steroidal, Astrocytes, Brain, Dopamine, Female, HLA-DR Antigens, Humans, Immunohistochemistry, Inflammation, Male, Neurons, Neurotoxins, Parkinson Disease, Substantia Nigra, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Microglia, Oxidative Stress, Intercellular Adhesion Molecule-1, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glial reactions in Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks